Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.

British Journal of Clinical Pharmacology
Gemma MatthysBin Peng

Abstract

Some non-anti-arrhythmic drugs delay cardiac repolarization, which can be measured as an increase in the QT interval. Delays in cardiac repolarization create an electrophysiological environment that favours the development of cardiac arrhythmias, which may lead to torsade de pointes, which can be fatal. As part of the clinical development of eltrombopag, a thorough QT(c) study was conducted to evaluate the effects of eltrombopag on cardiac repolarization at both therapeutic and supratherapeutic doses and to characterize the relationship between plasma eltrombopag concentrations and change in QT(c). This study found no clinically significant QT prolongation for eltrombopag when administered as 50 mg or 150 mg every day for 5 days. There were no safety or tolerability signals of clinical concern. A small incidence of ventricular premature beats was observed, but this was consistent with previously reported incidences in healthy volunteers without apparent heart disease. To evaluate the effect of eltrombopag on cardiac repolarization and to characterize the relationship between plasma eltrombopag concentrations and change in QT(c). This was a double-blind, placebo- and active-controlled, randomized, balanced four-period, crossover...Continue Reading

References

Mar 1, 1982·British Heart Journal·M T ViitasaloA Eisalo
May 31, 2003·Nature Reviews. Drug Discovery·Bernard Fermini, Anthony A Fossa
Mar 5, 2004·The New England Journal of Medicine·Dan M Roden
Jun 18, 2004·The New England Journal of Medicine·Panagiotis Korantzopoulos, Konstantinos Siogas
Mar 1, 2007·Blood·Julian M JenkinsConnie L Erickson-Miller
Nov 30, 2007·The New England Journal of Medicine·John G McHutchisonUNKNOWN TPL102357 Study Group
Nov 30, 2007·The New England Journal of Medicine·James B BusselJulian M Jenkins

❮ Previous
Next ❯

Citations

Apr 9, 2013·Cancer Chemotherapy and Pharmacology·Siobhan HayesEkaterina Gibiansky
Mar 5, 2013·Expert Opinion on Pharmacotherapy·Edoardo G Giannini, Nezam H Afdhal
Oct 15, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jane L LiesveldYuhchyau Chen
May 7, 2016·Drugs·Celeste B BurnessKarly P Garnock-Jones
Sep 2, 2018·Cancer Chemotherapy and Pharmacology·Vassilios AslanisTaoufik Ouatas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.